Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF JULY 22, 2022 SAM #7539
SOLICITATION NOTICE

Q -- Sequencing services on COVID-19 clinical samples from NYU Langone/School of Medicine

Notice Date

7/20/2022 11:06:14 AM
 

Notice Type

Presolicitation
 

NAICS

541380 — Testing Laboratories
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

NOI-NIAID-2135894
 

Response Due

7/27/2022 2:00:00 PM
 

Point of Contact

Dana Monroe, Phone: 4063759814
 

E-Mail Address

dana.monroe@nih.gov
(dana.monroe@nih.gov)
 

Description

PRE-SOLICITATION NOTICE **NOTICE OF INTENT NOI-NIAID-2135894 NAICS � 541380, Testing Laboratories This is a Notice of Intent, not a request for proposal.� The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with the NYU School of Medicine/NYU Langone Health to provide sequencing services on COVID-19 clinical samples for downstream bioinformatics analysis. The deep sequencing will look at host factors that contribute to disease progression. The sequencing will hope to reveal further insights into the host response to various COVID-19 treatments and correlate that with various health outcomes. The National Institute of Allergy and Infectious Diseases (NIAID) has a Systems Genomics Center (SGC) within the Division of Intermural Research (DIR). The SGS systems biology research program meets at the interface of molecular parasitology, microbiology, and genomics and focuses on the molecular basis of macroparasite (nematodes) adaptation to niches in their human hosts and microparasite (virus and bacteria) diversity and interaction in transmission and virulence.� As part of this research, SGC is continuing work on a project relating to COVID-19 host factors that contribute to disease progression.� Respiratory failure is associated with increased mortality in COVID-19 patients. There are no validated lower airway biomarkers to predict clinical outcome. NIH investigated whether bacterial respiratory infections were associated with poor clinical outcome of COVID-19 in a prospective, observational cohort of 589 critically ill adults, all of whom required mechanical ventilation. For a subset of 142 patients who underwent bronchoscopy, NIH quantified SARS-CoV-2 viral load, analyzed the lower respiratory tract microbiome using metagenomics and metatranscriptomics and profiled the host immune response. Acquisition of a hospital-acquired respiratory pathogen was not associated with fatal outcome. Poor clinical outcome was associated with lower airway enrichment with an oral commensal (Mycoplasma salivarium). Increased SARS-CoV-2 abundance, low anti-SARS-CoV-2 antibody response and a distinct host transcriptome profile of the lower airways were most predictive of mortality. The data provide evidence that secondary respiratory infections do not drive mortality in COVID-19 and clinical management strategies should prioritize reducing viral replication and maximizing host responses to SARS-CoV-2.� NIH has worked with NYU on other aspects of this project and changing vendors in the middle of critical experiments will negatively impact the validity of our experiments. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.� All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2135894 to Dana Monroe at dana.monroe@nih.gov, by 5:00 pm eastern time July 27, 2022. �All responses received by the closing date of this synopsis will be considered by the Government.� A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
 

Web Link

SAM.gov Permalink
(https://sam.gov/opp/bf26b0422fa84b7e97568fc139faf6a1/view)
 

Place of Performance

Address: Bethesda, MD 20892, USA

Zip Code: 20892

Country: USA
 

Record

SN06395342-F 20220722/220720230113 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |